Enoxaparin
Sodium is a low molecular weight heparin marketed under the trade
names Lovenox, Xaparin and Clexane, among others. It is an anticoagulant used to
prevent and treat deep vein thrombosis or pulmonary embolism, and is given as a
subcutaneous injection (by a health care provider or the patient). Its use is
evolving in acute coronary syndromes (ACS).
Enoxaparin Sodium is manufactured by Sanofi and is derived from the intestinal mucosa of pigs.
Enoxaparin Sodium injection, USP is a low molecular weight heparin [LMWH] indicated for:
Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness.
Inpatient treatment of acute DVT with or without pulmonary embolism
Outpatient treatment of acute DVT without pulmonary embolism.
Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction MI
Treatment of acute ST-segment elevation myocardial infarction STEMI managed medically or with subsequent percutaneous coronary intervention PCI
Reamore:Enoxaparin Sodium online
The article reprinted from:http://www.acid-lactic-bacteria.com/blog/post11/
Enoxaparin Sodium is manufactured by Sanofi and is derived from the intestinal mucosa of pigs.
Enoxaparin Sodium injection, USP is a low molecular weight heparin [LMWH] indicated for:
Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness.
Inpatient treatment of acute DVT with or without pulmonary embolism
Outpatient treatment of acute DVT without pulmonary embolism.
Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction MI
Treatment of acute ST-segment elevation myocardial infarction STEMI managed medically or with subsequent percutaneous coronary intervention PCI
Reamore:Enoxaparin Sodium online
The article reprinted from:http://www.acid-lactic-bacteria.com/blog/post11/
No comments:
Post a Comment